Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the…
By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical…
By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology…
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist…
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast…
Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi,…
By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher…
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…